Tesamorelin vs CJC-1295
Side-by-side comparison of Tesamorelin, CJC-1295 — mechanism, dosing, half-life, side effects, and research status.
| Attribute | Tesamorelin Tesamorelin (GHRH Analogue) Growth Hormone | CJC-1295 CJC-1295 (Modified GRF 1-29) Growth Hormone |
|---|---|---|
| Basics | ||
| Molecular type | GHRH Analogue | GHRH Analogue |
| Amino acids | 44 | 29 |
| Molecular weight | 5,135.8 Da | 3,368.9 Da |
| Half-life | ~30 min | 30 min (without DAC) / 7–8 days (with DAC) |
| Route(s) | Subcutaneous | Subcutaneous, Intramuscular |
| Mechanism & Research | ||
| Primary mechanism | Tesamorelin binds and activates pituitary GHRH receptors with the full-length 44-amino-acid native GHRH sequence, producing more complete pituitary signalling than the 29-amino-acid fragments (sermorelin, CJC-1295). Its … | CJC-1295 binds GHRH receptors on pituitary somatotroph cells, stimulating GH synthesis and increasing GH pulse amplitude. Unlike native GHRH (half-life <10 minutes), the modified amino acid substitutions in CJC-1295 resi… |
| Research status | FDA Approved | Research Compound |
| Evidence summary | Tesamorelin has the most extensive human clinical trial dataset of any GHRH analogue, accumulated during its FDA approval programme. Effects on visceral adiposity, metabolic parameters, and cognitive function have been s… | Phase 1/2 trials with CJC-1295 with DAC confirmed dose-dependent IGF-1 elevation lasting up to 14 days after single injection. CJC-1295 without DAC's pulsatile profile is primarily studied in combination with GHRPs. |
| Protocol & Dosing | ||
| Typical dose | 2 mg/day | 100–200 mcg (without DAC); 2mg every 2 weeks (with DAC) |
| Frequency | Once daily | 2–3x daily (without DAC); biweekly (with DAC) |
| Duration | 26–52 weeks (clinical) | 8–16 weeks |
| Timing | Before breakfast or bedtime | Without DAC: fasted, 2x daily ideally morning + bedtime. With DAC: any time, biweekly. |
| Safety | ||
| Common side effects |
|
|
| Contraindications |
|
|
| Anti-doping | Prohibited (WADA S2) | Prohibited (WADA S2) |
| Deeper reading | ||
| Related peptides | CJC-1295, Sermorelin, AOD-9604 | Ipamorelin, Sermorelin, GHRP-2, Tesamorelin |
| Full profile | Read full Tesamorelin profile → | Read full CJC-1295 profile → |
Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.